Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China

NCT03029234 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03029234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2017
Completion date
June 4, 2021
Enrollment
126 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory multiple myeloma